From 01 May to 30 August 2026, the FASS consortium invites researchers from pharma, biotech and academia to apply for measurements on the F1. Approved samples are measured by the Biopharma group at the University of Santiago de Compostela (USC) on a FASS-designated F1 instrument.
You retain full ownership of your samples and your data. There is no charge for the measurements; applicants cover the shipping of their samples.

Fast. Robust. Economical.

The F1 turns solubility and aggregation profiling into a plate-based workflow that fits real R&D timelines: 384-well plates measured in approximately 15 minutes, around ~100× faster and ~100× less compound than traditional HPLC-based solubility workflows. It is non-destructive and works across small molecules, peptides, oligonucleotides, PROTACs, macrocycles and high-concentration biologics — including the modalities where DLS, SLS and HPLC saturate or fall short.

The F1 is not an HPLC replacement. It is a triage layer that runs before HPLC and downstream assays, so the right molecules advance with confidence and the wrong ones do not consume scarce resources.

Sample types accepted

• Small molecules
• Peptides & oligonucleotides
• PROTACs, molecular glues, macrocycles
• Proteins & biologics (incl. high-conc. formulation)

Aqueous medium or DMSO, with cosolvents, excipients and salts. Working volume per well 50–300 µL.

For more information and application visit the Fass website: https://fass-solubility.eu/open-solubility-platform/#what